Does DATOPOTAMAB DERUXTECAN-DLNK Cause Interstitial lung disease? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Interstitial lung disease have been filed in association with DATOPOTAMAB DERUXTECAN-DLNK. This represents 4.2% of all adverse event reports for DATOPOTAMAB DERUXTECAN-DLNK.
7
Reports of Interstitial lung disease with DATOPOTAMAB DERUXTECAN-DLNK
4.2%
of all DATOPOTAMAB DERUXTECAN-DLNK reports
1
Deaths
3
Hospitalizations
How Dangerous Is Interstitial lung disease From DATOPOTAMAB DERUXTECAN-DLNK?
Of the 7 reports, 1 (14.3%) resulted in death, 3 (42.9%) required hospitalization.
Is Interstitial lung disease Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DATOPOTAMAB DERUXTECAN-DLNK. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does DATOPOTAMAB DERUXTECAN-DLNK Cause?
Disease progression (49)
Off label use (31)
Stomatitis (27)
No adverse event (22)
Nausea (11)
Prescribed underdose (9)
Death (7)
Dyspnoea (6)
Mucosal inflammation (5)
Product prescribing issue (5)
What Other Drugs Cause Interstitial lung disease?
METHOTREXATE (3,049)
RITUXIMAB (2,458)
PEMBROLIZUMAB (2,113)
PREDNISONE (1,850)
CYCLOPHOSPHAMIDE (1,725)
NIVOLUMAB (1,538)
AMIODARONE (1,421)
DOXORUBICIN (1,352)
ETANERCEPT (1,267)
ADALIMUMAB (1,250)
Which DATOPOTAMAB DERUXTECAN-DLNK Alternatives Have Lower Interstitial lung disease Risk?
DATOPOTAMAB DERUXTECAN-DLNK vs DAUNORUBICIN
DATOPOTAMAB DERUXTECAN-DLNK vs DAXIBOTULINUMTOXIN A-LANM
DATOPOTAMAB DERUXTECAN-DLNK vs DAYTRANA
DATOPOTAMAB DERUXTECAN-DLNK vs DECITABINE
DATOPOTAMAB DERUXTECAN-DLNK vs DEFERASIROX